Description
Avastin is a vascular endothelial growth factor–specific angiogenesis inhibitor indicated for the treatment of:
1. Metastatic colorectal cancer,
- chemotherapy for first– or second–line treatment.
2. Non–squamous non–
- for first line treatment of un-resectable, locally advanced, recurrent or
- metastatic disease.
3. Metastatic breast cancer,
- not received chemotherapy for metastatic HER2–negative breast cancer.
– Effectiveness based on improvement in progression–free survival. No data available demonstrating improvement in disease–related symptoms or survival with Avastin.
– Not indicated for disease progression following anthracycline and taxane chemotherapy administered for metastatic disease.
4. Glioblastoma, as a single agent for adult patients with progressive disease following prior therapy.
– Effectiveness based on improvement in objective response rate. No data available demonstrating improvement in disease–related symptoms or survival with Avastin.
5. Metastatic renal cell carcinoma with interferon alfa.
Side-effects/Adverse Reactions:
Most common adverse reactions incidence (>10% and at least twice the control arm rate) are epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, rectal hemorrhage, lacrimation disorder, back pain and exfoliative dermatitis.
Manufactured by Roche
